Would you offer any additional adjuvant therapy after platinum based chemotherapy for patients with resected PD-L1 positive Stage II-III lung adenocarcinoma with EGFR exon 20 insertions?  

At this time, I would likely offer adjuvant immunotherapy as in KEYNOTE-091 NCT02504372 (pembrolizumab) or IMpower010 (atezolizumab). Though EGFR ex20ins mutations occur mainly in non-smoking patients with NSCLC, a population that tends to benefit less from immunotherapy, there is little data to sug...